Cargando…
The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report
Medication‐related osteonecrosis of the jaws (MRONJ) is a serious debilitating disease resulting from long‐term treatment with Antiresorptive drugs such as Bisphosphonates or Denosumab, which significantly affects patients' quality of life. A 43‐year‐old female patient with stage 4 breast cance...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675097/ https://www.ncbi.nlm.nih.gov/pubmed/38028038 http://dx.doi.org/10.1002/ccr3.8259 |
_version_ | 1785149781608235008 |
---|---|
author | Asfour, Maan Ahmad Rafik Aljoujou, Abeer Ahmad Saifo, Maher Sadik Jabban, Haya A. L. |
author_facet | Asfour, Maan Ahmad Rafik Aljoujou, Abeer Ahmad Saifo, Maher Sadik Jabban, Haya A. L. |
author_sort | Asfour, Maan Ahmad Rafik |
collection | PubMed |
description | Medication‐related osteonecrosis of the jaws (MRONJ) is a serious debilitating disease resulting from long‐term treatment with Antiresorptive drugs such as Bisphosphonates or Denosumab, which significantly affects patients' quality of life. A 43‐year‐old female patient with stage 4 breast cancer and treated with Zoledronic Acid for bone metastases was referred to the Department of Oral Medicine at the Faculty of Dentistry, Damascus University. The main complaint was pain in the right maxilla. Intraoral examination showed an exposure of necrotic bone in the right maxillary region with presence of purulent exudate. The treatment plan was discussed with the patient. Treatment included resection of all necrotic bone and application of Advanced platelet‐rich fibrin (A‐PRF) clots and membranes. Follow‐up and outcome were conducted by clinical measures to assess healing and recurrence (6‐month follow‐up). Topical treatment with A‐PRF demonstrated a reduction in pain and resulted in complete wound healing within 30 days. A‐PRF stimulates the release of growth factors and chemotaxis involved in tissue repair mechanisms. This method seemed to be effective in the treatment of MRONJ. |
format | Online Article Text |
id | pubmed-10675097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106750972023-11-25 The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report Asfour, Maan Ahmad Rafik Aljoujou, Abeer Ahmad Saifo, Maher Sadik Jabban, Haya A. L. Clin Case Rep Case Report Medication‐related osteonecrosis of the jaws (MRONJ) is a serious debilitating disease resulting from long‐term treatment with Antiresorptive drugs such as Bisphosphonates or Denosumab, which significantly affects patients' quality of life. A 43‐year‐old female patient with stage 4 breast cancer and treated with Zoledronic Acid for bone metastases was referred to the Department of Oral Medicine at the Faculty of Dentistry, Damascus University. The main complaint was pain in the right maxilla. Intraoral examination showed an exposure of necrotic bone in the right maxillary region with presence of purulent exudate. The treatment plan was discussed with the patient. Treatment included resection of all necrotic bone and application of Advanced platelet‐rich fibrin (A‐PRF) clots and membranes. Follow‐up and outcome were conducted by clinical measures to assess healing and recurrence (6‐month follow‐up). Topical treatment with A‐PRF demonstrated a reduction in pain and resulted in complete wound healing within 30 days. A‐PRF stimulates the release of growth factors and chemotaxis involved in tissue repair mechanisms. This method seemed to be effective in the treatment of MRONJ. John Wiley and Sons Inc. 2023-11-25 /pmc/articles/PMC10675097/ /pubmed/38028038 http://dx.doi.org/10.1002/ccr3.8259 Text en © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Case Report Asfour, Maan Ahmad Rafik Aljoujou, Abeer Ahmad Saifo, Maher Sadik Jabban, Haya A. L. The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report |
title | The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report |
title_full | The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report |
title_fullStr | The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report |
title_full_unstemmed | The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report |
title_short | The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report |
title_sort | use of advanced‐platelet rich fibrin (a‐prf) in the management of medication‐related osteonecrosis of the jaw (mronj): a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675097/ https://www.ncbi.nlm.nih.gov/pubmed/38028038 http://dx.doi.org/10.1002/ccr3.8259 |
work_keys_str_mv | AT asfourmaanahmadrafik theuseofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport AT aljoujouabeerahmad theuseofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport AT saifomahersadik theuseofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport AT jabbanhayaal theuseofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport AT asfourmaanahmadrafik useofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport AT aljoujouabeerahmad useofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport AT saifomahersadik useofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport AT jabbanhayaal useofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport |